What JYNARQUE Does

JYNARQUE® (tolvaptan) may help change the course of your disease

Kidney function

JYNARQUE is the first-and-only FDA-approved treatment proven to slow kidney function decline in adults who are at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)

JYNARQUE slows the decline in kidney function

Data from a 1-year clinical study of patients with chronic kidney disease (CKD) stages 2 to 4

1 yea r star t Stage 3b Stage 3a Stage 4 mL/min/1.73m 2 30 45 Speed of decline slowed by 35% Kidney function (average eGFR) over time* Difference JYNARQUE made JYNARQUE Placebo
Difference JYNARQUE made Placebo JYNARQUE 1 yea r star t Stage 3b Stage 3a Stage 4 mL/min/1.73m 2 3 0 4 5 Speed of decline slowed by 35% . Kidney function (average eGFR) over time*

Want even more details?
Read about this study in the New England Journal of Medicine

*Kidney function or estimated glomerular filtration rate (eGFR) is measured in units of mL/min/1.73m2.

Data from a 3-year clinical study of patients with chronic kidney disease (CKD) stages 1 to 3

Difference JYNARQUE made JYNARQUE Placebo 1 year start 2 years 3 years Stage 2 Stage 1 Stage 3a mL/min/1.73m 2 60 90 Kidney function (average eGFR) over time* Speed of decline slowed by 26%
Speed of decline slowed by 26% . 1 year start 2 years 3 years Stage 2 Stage 1 Stage 3a mL/min/1.73m 2 60 90 Kidney function (average eGFR) over time* Difference JYNARQUE made Placebo JYNARQUE

Want even more details?
Read about this study in the New England Journal of Medicine

*Kidney function or estimated glomerular filtration rate (eGFR) is measured in units of mL/min/1.73m2.

Kidney pain

Patients taking JYNARQUE had less kidney pain

In a clinical trial of ADPKD patients with CKD stages 1 to 3,

patients taking JYNARQUE had

36% fewer pain events

requiring medication or other treatment than those taking placebo.

 

Treatment was defined as:

  • Prescribed leave
  • Surgery
  • Radiologic treatment

Disease stages

JYNARQUE works at different stages of disease

JYNARQUE is for people at risk of having fast-progressing ADPKD.

JYNARQUE is appropriate in adults at stages 1 to 4 of CKD with rapidly progressing disease. Whether your GFR is 90 or 30, JYNARQUE may help.

2 3 4 1 STAGES OF CKD Study 1 Study 2
4 3 2 1 Study 1 Study 2 STAGES OF CKD

JYNARQUE is a long-term treatment that has been studied in many patients

  • JYNARQUE has been studied in over 3000 people with ADPKD
  • For people who do not have kidney failure, JYNARQUE may help by slowing the loss of function for as long as they keep taking it
  • JYNARQUE may change the course of your disease by slowing kidney function decline as it works over a period of years. As you take JYNARQUE, remember that it is a long-term treatment and can take time to make a difference

How JYNARQUE works

How does JYNARQUE work?

JYNARQUE works by targeting one of the mechanisms that lead cysts to grow in people with ADPKD.

CYST JYNARQUE works by preventing vasopressin from binding in the kidneys, making it harder for cysts to grow J JYNARQUE Receptor Vasopressin is a hormone that maintains the volume of water in the fluid space surrounding the cells. People with ADPKD have too much vasopressin, causing kidney cysts to grow. V V V V V V V V V V V
V Vasopressin is a hormone that maintains the volume of water in the fluid space surrounding the cells. People with ADPKD have too much vasopressin, causing kidney cysts to grow. CYST J JYNARQUE Receptor V V V V V V V V V V JYNARQUE works by preventing vasopressin from binding in the kidneys, making it harder for cysts to grow

For illustration purposes only.

Learn about the most common side effects this causes 

Video

Is JYNARQUE For You?

COVID-19 UPDATE

With the COVID-19 situation constantly developing, your health is our top priority. We hope that you and your families are staying safe and healthy during this unprecedented time.

If you are currently taking JYNARQUE® (tolvaptan), we encourage you to stay in close contact with your healthcare professional team regarding regular appointments and treatment management plans.

At this time, there is no expected impact on medication supply.

During the current COVID-19 pandemic, the JYNARQUE® (tolvaptan) REMS Program requirements remain in effect, as the health of patients who use this product is our top priority. Ongoing blood monitoring required by the REMS Program is extremely important due to the potential risk of serious liver injury from treatment with JYNARQUE. For these lab requirements during COVID-19 pandemic, we are able to temporarily offer our Mobile Phlebotomy Collection Service at no-cost for all patients taking JYNARQUE who prefer to have the REMS required blood work collected at home.

In helping patients who have lost a job or health insurance coverage due to the COVID-19 pandemic and to get through these challenging times, we have extended our Patient Support Program to provide ‘no-cost’ access for patients in the U.S. who are taking JYNARQUE. Please call Otsuka Patient Support at 1-855-242-7787 for more information on both programs.

For help accessing JYNARQUE, go to www.otsukapatientsupport.com/jynarque or call Otsuka Patient Support at 1-855-242-7787. The nurses at Otsuka Patient Support can answer questions related to Product Accessibility, Reimbursement and connecting patients to local treatment sites in their community.

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

September 202010US20EBC0103

COVID-19 UPDATE

With the COVID-19 situation constantly developing, your health is our top priority. We hope that you and your families are staying safe and healthy during this unprecedented time.

If you are currently taking JYNARQUE® (tolvaptan), we encourage you to stay in close contact with your healthcare professional team regarding regular appointments and treatment management plans.

At this time, there is no expected impact on medication supply.

During the current COVID-19 pandemic, the JYNARQUE® (tolvaptan) REMS Program requirements remain in effect, as the health of patients who use this product is our top priority. Ongoing blood monitoring required by the REMS Program is extremely important due to the potential risk of serious liver injury from treatment with JYNARQUE. For these lab requirements during COVID-19 pandemic, we are able to temporarily offer our Mobile Phlebotomy Collection Service at no-cost for all patients taking JYNARQUE who prefer to have the REMS required blood work collected at home.

In helping patients who have lost a job or health insurance coverage due to the COVID-19 pandemic and to get through these challenging times, we have extended our Patient Support Program to provide ‘no-cost’ access for patients in the U.S. who are taking JYNARQUE. Please call Otsuka Patient Support at 1-855-242-7787 for more information on both programs.

For help accessing JYNARQUE, go to www.otsukapatientsupport.com/jynarque or call Otsuka Patient Support at 1-855-242-7787. The nurses at Otsuka Patient Support can answer questions related to Product Accessibility, Reimbursement and connecting patients to local treatment sites in their community.

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

September 202010US20EBC0103